key: cord-0750886-s57fymbj
authors: RUIZ, S.; CONCORDET, D.; LANOT, T.; GEORGES, B.; GOUDY, P.; BAKLOUTI, S.; MANE, C.; LOSHA, E.; VINOUR, H.; ROUSSET, D.; LAVIT, M.; MINVILLE, V.; CONIL, J-M; GANDIA, P.
title: Hydroxychloroquine lung pharmacokinetics in critically ill patients infected with COVID-19
date: 2020-11-28
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106247
sha: 9e5b91ca591589616559c9abe489dcad65a7571d
doc_id: 750886
cord_uid: s57fymbj

Different dosage regimens of hydroxychloroquine were used to manage COVID-19 patients, with no information on the lungs’ exposure in this population. The aim of our study was to evaluate hydroxychloroquine concentrations in the lung epithelial lining fluid (ELF) in patients infected with COVID-19. This study is a retrospective, observational, multicenter, pharmacokinetics study of hydroxychloroquine in critically ill patients. No additional interventions or additional samples compared to standard care of these patients were conducted in our teaching hospital. We included all intubated COVID-19 patients treated with crushed hydroxychloroquine tablets, regardless of the dosage administered by the nasogastric tube. Blood and bronchoalveolar lavage (BAL) samples (n= 28) were collected from 22 COVID-19 patients and the total hydroxychloroquine concentrations in epithelial lining fluid were estimated. Median hydroxychloroquine plasma concentrations were of 0.09 [0.06; 0.14] mg/l and 0.07 [0.05; 0.08] mg/l for 400 mg x 1/day and 200 mg x 3/day, respectively. Median hydroxychloroquine ELF concentrations were of 3.74 [1.10; 7.26] mg/l and 1.81 [1.20; 7.25] for 400 mg x 1/day and 200 mg x 3/day, respectively. The median ratio of ELF/plasma concentrations was of 40.0 [7.3; 162.7] and 21.2 [18.4; 109.5] for 400 mg x 1/day and 200 mg x 3/day, respectively. Exposure in the ELF is likely to be underestimated due to the concentrations of plasma hydroxychloroquine. In clinical practice, low plasma concentrations should not induce an increase in drug dosage because the lung exposure may already be high.

Based on the in vitro work carried out against SARS-CoV-2 and preliminary clinical data, hydroxychloroquine is currently being used in the management of COVID-19 patients [1, 2] .

Hydroxychloroquine may have an antiviral action through three main mechanisms: (1) viral entry prevention, (2) impairment of viral replication and (3) pleiotropic action on the human immune system through immuno-modulating activity [3] . The various in vitro studies have shown that the EC 50 of hydroxychloroquine ranged from 0.72 to 4.4 µM (i.e. 0.241 to 1.4 mg/l) at 48 hours and 72 hours post-infection, respectively [3] [4] [5] . Pending the results of robust clinical trials and due to the lack of pharmacokinetic-pharmacodynamic information in COVID-19 patients, and in accordance with the National French Team, AC43-ANRS/STP-SFPT, different dosage regimens were applied in Toulouse University Hospital (France) (200 mg x 3 / day; 400 mg x 2 on day 1 then 200 mg x 3 / day; 400 mg x 2 on day 1 then 400 mg / day; and at least for ICU patients, 600 mg x 2 on day 1 then 400 mg/day) in order to reach pharmacokinetic equilibrium as quickly as possible [6] . Regardless of the dosage regimen, plasma concentration was monitored in order to evaluate individual drug exposure. It has been proven that the plasma concentrations measured in COVID-19 patients tended to be lower than the values reported in SLE patients, in particular for the standard regimen of "200 mg x 3/day" [7] . These preliminary results suggest that hydroxychloroquine concentrations are unlikely to be adequately predicted using the pharmacokinetic models derived from patients receiving hydroxychloroquine for SLE or rheumatoid arthritis treatment [8] . 5 As the apparent volume of distribution of hydroxychloroquine is so large in volunteers as well as in malaria patients (≈ 5 000 l for the blood volume of distribution and ≈ 40 000 l for the plasma volume, at steady state) [9, 10] , it can be suggested that the hydroxychloroquine gets trapped in the red cells and granulocytes [9, 11, 12] and probably in various tissues [10] . It could be assumed that the same occurs for COVID-19 patients. Consequently, it is natural to question the concentration of hydroxychloroquine at the infectious site (i.e. the lung) [13] .

Unfortunately, this information is not available. A lung biopsy is the most informative approach. Even if a biopsy is a mixture of both intra-and extra-cellular matrices usually homogenised so as to determine a mean concentration [14] , hydroxychloroquine gets trapped in the cells suggesting this drug is more likely present in the cells rather than outside.

However, this option would be highly intrusive and an alternative approach would be to evaluate the hydroxychloroquine concentration in lung epithelial lining fluid (ELF) at the bedside of intensive care unit (ICU) patients [15, 16] .

Drug concentration in ELF can be inferred based on the concentration of hydroxychloroquine in the bronchoalveolar lavage (BAL) fluid and the concentration of urea both in the plasma and the BAL fluid [17] . This method is not new and is usually applied to explore the lung diffusion of antibiotics in ICU patients. Consequently, when available, BAL fluid can be used as a kind of "quality control" used to obtain information on the degree of impregnation in the lung for a short period (10-15 days) of treatment.

The aim of our study was to evaluate hydroxychloroquine in the lung's ELF in COVID-19 patients in order to estimate the level of lung exposure. 6 

This study is a retrospective, observational, multicentre, pharmacokinetic study of hydroxychloroquine in critically ill patients. We included all intubated COVID-19 patients treated with crushed hydroxychloroquine tablets, regardless of the dosage administered by nasogastric tube.

According to the guidelines established by the French National AC43-ANRS/STP-SFPT Team in March/April 2020, blood samples were collected at different time points (from 48h to 192h) during clinical management of COVID-19 patients after hydroxychloroquine initiation and 30 minutes before drug administration (i.e. trough concentration). In plasma, the steady state is supposed to be reached in 48 hours [18] .

As part of our standard practice for monitoring patients with acute respiratory distress syndrome (ARDS) who are at high risk for infectious complications, and in this particular context of COVID-19, a mini-bronchoalveolar lavage (BAL) (twice 20 ml of physiological saline) was systematically performed 7 days (+/-2 days) after treatment initiation or in the event of a new respiratory degradation, for microbiological monitoring purposes (bacteriology, mycology and viral replication of SARS-CoV-2). A leftover volume of approximately 500 µl remained after these microbiological investigations, which was used to determine the hydroxychloroquine concentration. BAL sampling was carried out between two dose administrations, with no specific time imposed. Except for one case, only the BALs for which plasma determinations were performed within 48 hours before or after collection were included.

Hydroxychloroquine in plasma and BAL fluid concentrations were determined using a chromatographic analytical method, validated as per FDA guidelines. All BAL sample 7 preparations included a protein precipitation and a virus inactivation step in a methanol solution. The HCQ dosage method presents a lower limit of quantitation (LLOQ) of 0.05 mg/l in the plasma and 0.01 mg/l in the BAL fluid, an upper limit of quantitation (ULOQ) of 2 mg/l in the plasma and the BAL fluid, and an intra-and inter-day variability of <4% and <10% respectively. When plasma concentrations were <LOQ, the value was set to 0.025 mg/L (i.e. half the LLOQ). The plasma samples were stored at +4°C before analysis, for a period of 24h maximum. The BAL fluid samples were stored at -80°C before analysis, for a period of 30 days maximum. Previous studies have shown that hydroxychloroquine was stable in the whole blood under these conditions [19] . As whole blood is a complex matrix, in which xenobiotics tend to be less stable than other biological fluids, we considered that hydroxychloroquine was also stable in plasma and BAL fluid in these conditions. Urea is used as an endogenous marker of ELF because urea, a small and relatively nonpolar molecule, can freely travel across membranes to reach the outer surfaces of alveoli. The concentration of urea in ELF (Urea ELF ) is considered to be same as in the serum urea (Urea serum ) concentration, implying complete distribution. Therefore, the volume of ELF (V ELF ) is adjusted for excess exogenous water using the following equation: intra-and inter-day variability < 2% and <3%, respectively. Safety practices require a greater 8 level of caution when handling respiratory specimen from SARS-CoV-2 positive patients [20] . Thus, urea concentrations in BAL was assayed using a gas chromatographya mass spectrometry method which included a protein precipitation and virus inactivation step in a methanol solution. A LLOQ of 0.1 mmol/l, and a ULOQ of 20 mmol/l were achieved.

Precision assays showed an intra-day variability < 9% and an inter-day variability < 10%.

BAL fluid samples were stored at -80°C before analysis, for a period of 60 days maximum.

Previous studies have shown that urea was stable in serum in these conditions [21] .

Continuous data was expressed as median (25th-75th percentiles) and categorical variables in numbers (percentages). The relationship between the plasma and ELF concentrations and the other parameters was assessed by simple linear regression. The analysis was performed using the MedCalc®15 statistical software program (Ostend, Belgium). p < 0.05 was considered to be statistically significant.

This study is entered in the Toulouse University Hospital register of retrospective studies (registration number: RnIPH 2020-33) and is covered by MR-004 (CNIL number: 2206723 v 0). This study was approved by Toulouse University Hospital and ethical requirements were entirely respected. 9 

The values of the BAL fluid hydroxychloroquine concentration were determined 7 to 12 days after treatment initiation. For one point, the time from blood collection to BAL was 9.8 days, but the plasma concentration was at stead-state. Table 2 ).

The relationship between ELF and the plasma hydroxychloroquine concentration is presented in Figure 1 .

No relationship was observed between the measured hydroxychloroquine concentrations and the biological parameters characterising renal and hepatic functions (Supplementary Table 1 ).

As previously reported for many anti-infective drugs used to treat pulmonary infections, ELF concentration gives information on the intra-and extracellular lung exposure [15, 16, 22] .

However, this approach is essentially reserved for clinical research as the therapeutic monitoring of anti-infective drugs in ELF is determined by practical and organisational constraints. Firstly, performing a BAL requires that the operator be trained and that the patient be stable enough to tolerate the serum injection in such way that it is only exceptionally carried out on non-intubated patients. Secondly, drug quantification has to be performed in an unconventional matrix (i.e. BAL) with a very sensitive analytical method (i.e. more often LC-MS/MS). In the special case of COVID-19 patients, the BAL is contaminated by SARS-CoV-2, thus imposing a specific and time consuming pre-analytical process.

We were able to gather all these conditions in order to assess whether all ELF concentrations are higher than plasma concentrations, despite the variability of ELF values. The significant variability in ELF concentrations may be explained in part by the BAL sampling. In fact, even if the injection volume were standardised (2 x 20 ml), the dwell time and the aspiration pressure cannot be strictly identical [23] . Cells can also be part of the ELF, especially macrophages, and may be lysed when measuring the drug concentration. Depending on their quantity, the lysis of these cells may induce an increase in the hydroxychloroquine concentration [11, 17] . As no measurement of the cell burden in the BAL sample was performed due to insufficient BAL volumes available for pharmacokinetic exploration, this lack of information has to be considered as a limitation of our study. Indeed, the cell burden in the BAL sample is likely associated with the ELF hydroxychloroquine concentration (i.e. the more the cells, the higher the concentrations). 11 Collecting blood and BAL samples at a different moment (day and/or time) and the potential post-dose discrepancy between the blood sample and the collection of BAL, could appear as limitating the interpretation of the ELF/plasma concentrations ratios. However, hydroxychloroquine presents a large volume of distribution with deep compartments (i.e. lung, spleen, melanin-containing tissues… [3] leading to different kinetic profiles in the plasma and lung tissue [24] . Indeed, half-life elimination is likely to be short in the plasma of COVID-19 patients [7, 18] as opposed to deep compartments. The blood samples have always been taken at steady state while the BALs could be collected always after the plasma concentration peak. Indeed, the staff in charge of carrying out the BALs was warned of this constraint. Furthermore, a flat kinetic profile was expected in the lung tissue [14] . As a consequence, it seems reasonable to suppose that ELF/plasma concentrations ratios do not change between administrations, once the steady state has been reached. In fact, the ideal solution would consist in determining the area under the time-concentration curve (AUC) in both plasma and BAL matrices at steady state and to calculate the AUC ratio. This option is not feasible and not ethical for critically ill patients presenting ARDS because multiple BALs would alter the gas exchanges between alveoli and capillaries. It would worsen PaO2/FiO2 ratios (the ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2 expressed as a fraction)).

However, as our data was retrospectively collected from a small population of ICU patients, one limitation of our study is that the inter-individual variability of the plasma and ELF hydroxychloroquine concentrations likely under/overestimates the actual inter-individual value.

Our results show that hydroxychloroquine concentrations in the lung are higher than in the ELF. Passage from the blood compartment to the ELF involves passing through the pulmonary epithelial cells (i.e. prime target for the replication of SARS-CoV-2 [17, 25, 26] ) in which hydroxychloroquine is most likely accumulated with pharmacokinetic hysteresis.

Hydroxychloroquine's mechanism of action is poorly elucidated, but includes, among others, the increase in endolysosomal pH necessary for viral fusion. The initial fusion between the viral and the cellular membranes (e.g. lung epithelial cells) requires an interaction between the surface proteins of the two partners, and this interaction can only take place under particular acidic conditions, through the phenomenon of endocytosis. The inability to obtain the ideal pH can block this process, and it is probably through this means that hydroxychloroquine may act. Other properties may be involved: modification in the glycosylation of angiotensin converting enzyme-2, the receptor that SARS-CoV-2 uses to enter the cells and/or posttranslational modification of some viral proteins [27] . In addition, viral invasion may also trigger a massive margination of the phagocytic cells to the infection site, which may deliver increased amounts of hydroxychloroquine [28] . But, in the absence of clear information on the influence of the inflammatory status reported in COVID-19 patients as to the accumulation of hydroxychloroquine in lungs, this point should be considered as a limit of our study.

Plasma concentration is not predictive of lung concentration, as shown in Figure 1 . Therefore, drug dosage determinations in studies assuming equilibrium between epithelium and plasma concentrations may lead to overly high dosages [29] . hours post-infection, respectively [3] [4] [5] . However, EC 50 could be determined in Vero cell lines, but not in a human epithelial cell model [4] . This discrepancy may explain that hydroxychloroquine has not shown efficacy in clinical trials [29] . Thus, whether for a dose of 13 400 mg x 1 /day or 200 mg x 3 /day, the median ELF concentration of hydroxychloroquine is above the maximum EC 50 value. Therefore, both regimens lead to a median lung exposure that could be sufficient to eradicate the virus. However, the heterogeneity of EC 50 s raises the problem of selecting the "right" threshold used to determine the dosage, in particular through modelling techniques. In conclusion, despite all its imperfections, BAL fluid provides a rough idea of lung exposure. 

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

A pharmacological perspective of Chloroquine in SARS-CoV-2 infection

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial

Hydroxychloroquine in COVID-19 patients: what still needs to be known about the kinetics

Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19

A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers

Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax

Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases

Distribution of chloroquine in human blood fractions

Lung tissue distribution of drugs as a key factor for COVID-19 treatment

Tissue concentrations: do we ever learn?

Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia

Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia

Interpretation of antibiotic concentration ratios measured in epithelial lining fluid

Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus

Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: An application for pharmacokinetic studies

Safety Considerations in the Laboratory Testing of Specimens Suspected or Known to Contain the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Longterm stability of biochemical markers in pediatric serum specimens stored at -80 °C: a CALIPER Substudy

Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia

Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents

Plasma terminal half-life

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

We would like to thank Dr Marion Grare and Dr Sophie Cassaing for their help in sampling bronchoalveolar fluid, the technicians of the Pharmacokinetics and Toxicology Laboratory of Toulouse University Hospital, Magali Centelles for her help in data collection, and Della Hoy for her kind help proofreading the English.

Funding: This study was supported by internal funding.